Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8434484 | Cancer Letters | 2018 | 37 Pages |
Abstract
Non-small cell lung cancer (NSCLC) patients harboring EGFR-activating mutations initially respond to EGFR tyrosine kinase inhibitors (EGFR-TKIs) and have shown favorable outcomes. However, acquired drug resistance to EGFR-TKIs develops in almost all patients mainly due to the EGFR T790â¯M mutation. Here, we show that treatment with low-dose EGFR-TKI results in the emergence of the EGFR T790â¯M mutation and in the reduction of HSP70 protein levels in HCC827â¯cells. Erlotinib treatment inhibits HSP70 phosphorylation at tyrosine 41 and increases HSP70 ubiquitination, resulting in HSP70 degradation. We show that EGFR-TKI treatment causes increased DNA damage and enhanced gene mutation rates, which are secondary to the EGFR-TKI-induced reduction of HSP70 protein. Importantly, HSP70 overexpression delays the occurrence of Erlotinib-induced EGFR T790â¯M mutation. We further demonstrate that HSP70 interacts with multiple enzymes in the base excision repair (BER) pathway and promotes not only the efficiency but also the fidelity of BER. Collectively, our findings show that EGFR-TKI treatment facilitates gene mutation and the emergence of EGFR T790â¯M secondary mutation by the attenuation of BER via induction of HSP70 protein degradation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Xiang Cao, Yi Zhou, Hongfang Sun, Miao Xu, Xiaowen Bi, Zhihui Zhao, Binghui Shen, Fengyi Wan, Zhuan Hong, Lei Lan, Lan Luo, Zhigang Guo, Zhimin Yin,